



## Clinical trial results:

**A pharmacokinetic study of capecitabine in patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomach.**

### Summary

EudraCT number	2009-009908-39
Trial protocol	GB
Global end of trial date	23 October 2013

### Results information

Result version number	v1 (current)
This version publication date	08 July 2016
First version publication date	30 July 2015

### Trial information

#### Trial identification

Sponsor protocol code	CAP002
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00871273
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Cambridge University Hospitals NHS Foundation Trust
Sponsor organisation address	Hills Road, Cambridge University Hospitals NHS Foundation Trust, United Kingdom, CB2 0QQ
Public contact	Chief Investigator, Cambridge University Hospitals NHS Foundation Trust , 0044 1223216083, cctu.cancer@addenbrookes.nhs.uk
Scientific contact	Chief Investigator, Cambridge University Hospitals NHS Foundation Trust , 0044 1223216083, cctu.cancer@addenbrookes.nhs.uk

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 October 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 October 2013
Global end of trial reached?	Yes
Global end of trial date	23 October 2013
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To establish the pharmacokinetics (PK) of capecitabine in patients who have undergone a total gastrectomy

Protection of trial subjects:

The study was approved by a Research Ethics Committee and received authorisation from the Medicines and Healthcare Products Regulatory Authority. Patients received verbal and written information prior to consenting to the trial and had the time to consider their participation and opportunity to ask questions. Consenting patients had a series of screening tests and exams to ensure they were suitable for the study and that it was safe to proceed. The patients were monitored in the clinic every 3 weeks during the pre-operative and post-operative cycles of treatment for assessment and monitoring of safety. On registration to the trial, the patients were allocated a unique reference number to be used on all data and samples sent to the Sponsor which allowed their personal data to remain anonymous. Only the patients' direct care team had access to their recruited participants personal data during the study. Patients were allowed to withdraw their consent to the study at any time. Patients were withdrawn from the study if they demonstrated disease progression or unacceptable toxicity.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 July 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 13
Worldwide total number of subjects	13
EEA total number of subjects	13

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3
From 65 to 84 years	10
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The first patient was recruited on to the study on 29-Jul-2010. The last patient was recruited onto the study on 04-Mar-2013. Patients were recruited from Hospital Oncology clinics.

### Pre-assignment

Screening details:

Twenty-eight patients were approached for the trial. Of these, 15 did not enter the trial (8 patients declined to participate, 4 patients did not meet the inclusion criteria and 3 patients were not suitable for other reasons). Thirteen patients were screened and were subsequently registered for the trial.

### Period 1

Period 1 title	On-Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Capecitabine
-----------	--------------

Arm description:

All registered subjects, planned to receive capecitabine used as part of the ECX combination therapy

Arm type	Experimental
Investigational medicinal product name	Capecitabine
Investigational medicinal product code	
Other name	Xeloda (trade name)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

625 mg/m<sup>2</sup>, BID, for 21 days for 3 cycles pre-operatively and 3 cycles post-operatively

Number of subjects in period 1	Capecitabine
Started	13
Completed	2
Not completed	11
Adverse event, serious fatal	1
'Protocol Violation '	1
WHO PS ≥ 2	2
'Adverse event, serious non-fatal '	2
GIST tumour	1
Total gastrectomy not performed	1
'Adverse event, not serious '	2

Disease Progression	1
---------------------	---

## Baseline characteristics

### Reporting groups

Reporting group title	On-Study
-----------------------	----------

Reporting group description: -

Reporting group values	On-Study	Total	
Number of subjects	13	13	
Age categorical			
All registered subjects, planned to receive ECX therapy			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	3	3	
From 65-84 years	10	10	
85 years and over	0	0	
Age continuous			
All registered subjects, planned to receive ECX therapy			
Units: years			
arithmetic mean	68.5		
standard deviation	± 7.8	-	
Gender categorical			
All registered subjects, planned to receive ECX therapy			
Units: Subjects			
Female	2	2	
Male	11	11	
WHO performance status			
Units: Subjects			
WHO PS=0	7	7	
WHO PS=1	6	6	

### Subject analysis sets

Subject analysis set title	Full Analysis Set
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All subjects who entered the study for PK sampling

<b>Reporting group values</b>	Full Analysis Set		
Number of subjects	13		
Age categorical			
All registered subjects, planned to receive ECX therapy			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	3		
From 65-84 years	10		
85 years and over	0		
Age continuous			
All registered subjects, planned to receive ECX therapy			
Units: years			
arithmetic mean	68.5		
standard deviation	± 7.8		
Gender categorical			
All registered subjects, planned to receive ECX therapy			
Units: Subjects			
Female	2		
Male	11		
WHO performance status			
Units: Subjects			
WHO PS=0	7		
WHO PS=1	6		

## End points

### End points reporting groups

Reporting group title	Capecitabine
Reporting group description: All registered subjects, planned to receive capecitabine used as part of the ECX combination therapy	
Subject analysis set title	Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description: All subjects who entered the study for PK sampling	

### Primary: PK parameters for capecitabine AUC (0-infinity)

End point title	PK parameters for capecitabine AUC (0-infinity) <sup>[1]</sup>
End point description: PK parameters for capecitabine AUC (0-infinity): ratio of AUC cycle 4/cycle 1	
End point type	Primary
End point timeframe: cycle 1 to cycle 4	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single arm PK study to investigate whether there is a difference in AUC of capecitabine between cycle 4 and cycle 1, measured by the ratio of cycle 4/cycle 1. A total of 5 patients completed both cycles. The mean and standard deviation of this ratio is 2.93 and 1.41, respectively. Using the one-sample t-test, the p-value of the null hypothesis that the ratio =1 is 0.0373.

<b>End point values</b>	Capecitabine			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: ratio				
arithmetic mean (standard deviation)	2.93 (± 1.41)			

<b>Attachments (see zip file)</b>	CAP002 SAE listing/CAP002 EudraCT 2009-009908-39_SAE
-----------------------------------	------------------------------------------------------

### Statistical analyses

No statistical analyses for this end point



## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

From patient registration until 28 days after last study drug administration, regardless of the dose or causal relationship

---

Assessment type	Systematic
-----------------	------------

---

### Dictionary used

---

Dictionary name	NCI CTCAE
Dictionary version	3

---

Frequency threshold for reporting non-serious adverse events: 0 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Serious adverse events are reported in the file found in the uploaded attachment.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 July 2009	Substantial amendment in response to non-acceptance. Submission of trial-specific label.
18 September 2009	Changes to the protocol V2.0 dated 18-Sep-2009 and patient information sheet V2.0 dated 18-Sep-2009 and informed consent form V2.0 dated 18-Sep-2009
17 March 2010	Changes to the protocol V3.0 dated 17-Mar-2010, patient information sheet and informed consent form V3.0 dated 17-Mar-2010 and GP Letter V1.1 dated 17-Mar-2010

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported